An Exploratory Clinical Study on the Safety and Efficacy of Autologous NK Cells in the Treatment of Pulmonary Nodules

Exclusion Criteria

• •1. Subjects who are known to have allergic reactions, hypersensitivity reactions, intolerances or contraindications to any component of KN5001, or subjects with a history of severe allergic reactions;
• •2. Subjects with the following genetic syndromes: Fanconi syndrome, Kostmann syndrome, Shwachman syndrome or any known bone marrow failure syndrome;
• •3. Subjects with active or uncontrolled infections requiring parenteral antibiotics; Evidence of a serious active viral or bacterial infection or an uncontrolled systemic fungal infection;
• •4. Subjects with heart failure of grade III or IV according to the New York Heart Association (NYHA) cardiac function classification standard (see Appendix 1);
• •5. Subjects with a history of epilepsy or other central nervous system diseases;
• •6. Subjects with a history of malignant tumors, excluding patients with cured skin or cervical carcinoma in situ and patients with inactive tumors;
• •7. Subjects with a significant bleeding tendency, such as gastrointestinal bleeding, coagulopathy, hypersplenism, etc.;
• •8. Subjects with unstable angina, symptomatic congestive heart failure, or myocardial infarction in the past 6 months;
• •9. Females who are pregnant, lactating, or planning a pregnancy within six months;
• •10. Subjects who have received other clinical trial treatment within 3 months;
• •11. Any situation judged by the investigators that may increase the risk of the subjects or interfere with the clinical trial outcome.